ATE493980T1 - Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung - Google Patents

Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung

Info

Publication number
ATE493980T1
ATE493980T1 AT03783726T AT03783726T ATE493980T1 AT E493980 T1 ATE493980 T1 AT E493980T1 AT 03783726 T AT03783726 T AT 03783726T AT 03783726 T AT03783726 T AT 03783726T AT E493980 T1 ATE493980 T1 AT E493980T1
Authority
AT
Austria
Prior art keywords
transplant rejection
chronic transplant
prevent chronic
diamide derivative
subject
Prior art date
Application number
AT03783726T
Other languages
English (en)
Inventor
John Williams
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE493980T1 publication Critical patent/ATE493980T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03783726T 2002-11-21 2003-11-21 Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung ATE493980T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42833202P 2002-11-21 2002-11-21
PCT/US2003/037318 WO2004047825A1 (en) 2002-11-21 2003-11-21 Use of diamide derivatives for inhibiting chronic tissue transplant rejection

Publications (1)

Publication Number Publication Date
ATE493980T1 true ATE493980T1 (de) 2011-01-15

Family

ID=32393386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03783726T ATE493980T1 (de) 2002-11-21 2003-11-21 Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung

Country Status (9)

Country Link
US (2) US7687530B2 (de)
EP (1) EP1567138B1 (de)
JP (2) JP4928079B2 (de)
AT (1) ATE493980T1 (de)
AU (1) AU2003291134A1 (de)
DE (1) DE60335652D1 (de)
ES (1) ES2363914T3 (de)
PT (1) PT1567138E (de)
WO (1) WO2004047825A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408408C (en) 2000-05-12 2013-07-09 Genzyme Corporation Modulators of tnf- alpha signaling
PT1567138E (pt) * 2002-11-21 2011-04-11 Genzyme Corp Utilização de derivados de diamida para inibição de rejeição crónica de transplante
WO2004047826A1 (en) * 2002-11-21 2004-06-10 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
US8932808B1 (en) 2004-01-21 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
WO2006099421A2 (en) * 2005-03-14 2006-09-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
US20110201519A1 (en) 2008-08-18 2011-08-18 Sarwal Minnie M Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject
US9938579B2 (en) 2009-01-15 2018-04-10 The Board Of Trustees Of The Leland Stanford Junior University Biomarker panel for diagnosis and prediction of graft rejection
EP3185013B1 (de) 2009-12-02 2019-10-09 The Board of Trustees of the Leland Stanford Junior University Biomarker zur bestimmung eines allotransplantattoleranten phänotyps
WO2011119980A1 (en) 2010-03-25 2011-09-29 The Board Of Trustees Of The Leland Stanford Junior University Protein and gene biomarkers for rejection of organ transplants
WO2012139051A2 (en) 2011-04-06 2012-10-11 The Board Of Trustees Of The Leland Stanford Junior University Autoantibody biomarkers for iga nephropathy
EP2827861A4 (de) * 2012-03-19 2016-03-16 Aposignal Bioscience Llc Zusammensetzung und verfahren zur zellmodulation
US11931480B2 (en) 2016-02-16 2024-03-19 The Regents Of The University Of California Microporous annealed particle gels and methods of use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5958413A (en) 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5861382A (en) 1992-05-01 1999-01-19 Yeda Research And Development Co. Ltd. Methods for regulation of active TNF-α
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
CA2146647C (en) 1992-10-08 2009-05-05 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US6080407A (en) 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
JPH09510952A (ja) 1993-10-06 1997-11-04 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
DE4430128A1 (de) 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
DE4430127A1 (de) 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
US5932737A (en) * 1994-12-02 1999-08-03 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds for treatment of no-mediated diseases
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
ATE259235T1 (de) 1995-07-20 2004-02-15 Cell Eng Ag Zubereitung enthaltend glykane übereinstimmend mit transferrin glykaner als aktives prinzip für die induktion der immuntoleranz gegen antigene
IL115245A (en) 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
ATE215946T1 (de) * 1995-11-22 2002-04-15 Darwin Discovery Ltd Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
EP0942740B1 (de) 1996-12-06 2003-08-27 Amgen Inc., Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO1998039026A2 (en) 1997-03-07 1998-09-11 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
US5801193A (en) 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US6229878B1 (en) * 1998-01-21 2001-05-08 Lucent Technologies, Inc. Telephone answering method and apparatus
US6359061B1 (en) * 1999-03-19 2002-03-19 Isis Pharmaceuticals, Inc. Amide compound libraries
WO2000059874A1 (en) 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
WO2001034649A2 (en) 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
CA2408408C (en) * 2000-05-12 2013-07-09 Genzyme Corporation Modulators of tnf- alpha signaling
WO2001090074A2 (en) 2000-05-22 2001-11-29 Leo Pharma A/S BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)
WO2004003154A2 (en) 2002-06-26 2004-01-08 The Trustees Of Columbia Uninersity In The City Of New York Use of streptavidin to inhibit transplant rejection
WO2004047826A1 (en) * 2002-11-21 2004-06-10 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
PT1567138E (pt) * 2002-11-21 2011-04-11 Genzyme Corp Utilização de derivados de diamida para inibição de rejeição crónica de transplante

Also Published As

Publication number Publication date
EP1567138A1 (de) 2005-08-31
JP2006514013A (ja) 2006-04-27
PT1567138E (pt) 2011-04-11
US20040163654A1 (en) 2004-08-26
AU2003291134A1 (en) 2004-06-18
US20100256211A1 (en) 2010-10-07
ES2363914T3 (es) 2011-08-19
WO2004047825A1 (en) 2004-06-10
JP2010280725A (ja) 2010-12-16
DE60335652D1 (de) 2011-02-17
EP1567138B1 (de) 2011-01-05
JP4928079B2 (ja) 2012-05-09
US7687530B2 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
ATE493980T1 (de) Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
ATE534377T1 (de) Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
ATE447948T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
DE602007006419D1 (de) Verfahren zur verwendung von guava-extrakt und zusammensetzung mit guava-extrakt
MX2009011823A (es) Piridonacarboxamidas, agentes protectores de plantas utiles que contienen a estas y procedimientos para su preparacion y su utilizacion.
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
ATE513550T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
ATE444749T1 (de) Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
DE60316672D1 (de) Polycyclische verbindungen als potenten alpha2-adrenoceptor antagonisten
RS51190B (sr) Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
WO2006002763A3 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
TW200600084A (en) Anti-coronavirus compounds
ATE262330T1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE369856T1 (de) Verfahren zur behandlung von glaukom
ATE208144T1 (de) Verfahren und zusammensetzungen zur steigerung der anaerobe leistungsfähigkeit in geweben
ATE374025T1 (de) Verbindungen zur beseitigung und/oder linderung der anhedonie
SE0301947D0 (sv) New method and uses
ATE396717T1 (de) Verfahren zur behandlung von alkoholischer hepatitis
ATE350101T1 (de) Verwendung eines pyridazinon derivates zur behandlung des kongestiven herzversagens
DE602004030112D1 (de) Verfahren zur herstellung von ace hemmern
ATE383336T1 (de) Arylpyrrol mit antitubulinwirkung, arylfulran- und arylthiopenderivate, verfahren zur herstellung und verwendung als antimitotikum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties